Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04017962 · ClinicalTrials.gov registry record · Phase 2
A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT04017962: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04017962 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 102 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04017962, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
The purpose of this study is to determine of letermovir (LTC) is effective at preventing Cytomegalovirus (CMV) infection from returning in people who have already had CMV infection after a bone marrow transplant.
Interventions
- OTHER blood draw
- DRUG Letermovir Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2019-07-19 |
| Est. Completion | 2025-07-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04017962
The ClinicalTrials.gov registry entry for NCT04017962 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which blood draw is the first listed.
NCT04017962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04017962 about?
NCT04017962 is a clinical study titled "A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection". The purpose of this study is to determine of letermovir (LTC) is effective at preventing Cytomegalovirus (CMV) infection from returning in people who have already had CMV infection after a bone marrow transplant.
What is the current status of trial NCT04017962?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2019-07-19. Estimated completion is 2025-07-29.
What interventions are being tested in trial NCT04017962?
The interventions under investigation include: blood draw (OTHER), Letermovir Pill (DRUG).
Who is sponsoring clinical trial NCT04017962?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.